January 4, 2018 / 12:12 PM / 7 months ago

BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease

Jan 4 (Reuters) - Kamada Ltd:

* KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE

* KAMADA SAYS ANNOUNCED COLLABORATION WITH MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM

* KAMADA LTD - RECEIVED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE ALPHA-1 ANTITRYPSIN FOR PREEMPTION OF GVHD USING MAGIC BIOMARKERS

* KAMADA SAYS STUDY OF ALPHA-1-ANTITRYPSIN WILL BE INITIATED IN Q1 OF 2018

* KAMADA LTD - TOP-LINE RESULTS FROM ALPHA-1-ANTITRYPSIN STUDY ARE EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below